drugset / Trial / NCT03238651
A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)
Non-randomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 when administered in East Asian participants with NHL who do not have an effective standard treatment available and to characterize the plasma and urine pharmacokinetic (PK) of TAK-659 in East Asian participants with NHL.
Timeline
- Start
- 2017-08-01
- Primary completion
- 2020-08-17
- Completion
- 2020-08-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mivavotinib | Small molecule | 60 mg | Oral |
| Subject | mivavotinib | Small molecule | 80 mg | Oral |